Xiaoqing Xing1,2, Pengcheng Ma3, Qing Huang4, Xiemin Qi5, Bingjie Zou5, Jun Wei3, Lei Tao3, Lingjun Li3, Guohua Zhou6,7, Qinxin Song8. 1. Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China. 2. Department of Pharmacy, Hebei General Hospital, Shijiazhuang, 050051, China. 3. Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, 210042, China. 4. Jiangsu Institute for Food and Drug Control, Nanjing, 210008, China. 5. Department of Pharmacology, Jinling Hospital, Medical School of Nanjing University, No. 305, Zhongshan East Road, Nanjing, 210002, China. 6. Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China. ghzhou@nju.edu.cn. 7. Department of Pharmacology, Jinling Hospital, Medical School of Nanjing University, No. 305, Zhongshan East Road, Nanjing, 210002, China. ghzhou@nju.edu.cn. 8. Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China. songqinxin@cpu.edu.cn.
Abstract
INTRODUCTION: Pharmacogenetics and pharmacometabolomics are the common methods for personalized medicine, either genetic or metabolic biomarkers have limited predictive power for drug response. OBJECTIVES: In order to better predict drug response, the study attempted to integrate genetic and metabolic biomarkers for drug pharmacokinetics prediction. METHODS: The study chose celecoxib as study object, the pharmacokinetic behavior of celecoxib was assessed in 48 healthy volunteers based on UPLC-MS/MS platform, and celecoxib related single nucleotide polymorphisms (SNPs) were also detected. Three mathematic models were constructed for celecoxib pharmacokinetics prediction, the first one was mainly based on celecoxib-related SNPs; the second was based on the metabolites selected from a pharmacometabolomic analysis by using GC-MS/MS method, the last model was based on the combination of the celecoxib-related SNPs and metabolites above. RESULTS: The result proved that the last model showed an improved prediction power, the integration model could explain 71.0% AUC variation and predict 62.3% AUC variation. To facilitate clinical application, ten potential celecoxib-related biomarkers were further screened, which could explain 68.3% and predict 54.6% AUC variation, the predicted AUC was well correlated with the measured values (r = 0.838). CONCLUSION: This study provides a new route for personalized medicine, the integration of genetic and metabolic biomarkers can predict drug response with a higher accuracy.
INTRODUCTION: Pharmacogenetics and pharmacometabolomics are the common methods for personalized medicine, either genetic or metabolic biomarkers have limited predictive power for drug response. OBJECTIVES: In order to better predict drug response, the study attempted to integrate genetic and metabolic biomarkers for drug pharmacokinetics prediction. METHODS: The study chose celecoxib as study object, the pharmacokinetic behavior of celecoxib was assessed in 48 healthy volunteers based on UPLC-MS/MS platform, and celecoxib related single nucleotide polymorphisms (SNPs) were also detected. Three mathematic models were constructed for celecoxib pharmacokinetics prediction, the first one was mainly based on celecoxib-related SNPs; the second was based on the metabolites selected from a pharmacometabolomic analysis by using GC-MS/MS method, the last model was based on the combination of the celecoxib-related SNPs and metabolites above. RESULTS: The result proved that the last model showed an improved prediction power, the integration model could explain 71.0% AUC variation and predict 62.3% AUC variation. To facilitate clinical application, ten potential celecoxib-related biomarkers were further screened, which could explain 68.3% and predict 54.6% AUC variation, the predicted AUC was well correlated with the measured values (r = 0.838). CONCLUSION: This study provides a new route for personalized medicine, the integration of genetic and metabolic biomarkers can predict drug response with a higher accuracy.
Entities:
Keywords:
Celecoxib; Metabolites; Personalized medicine; Pharmacometabolomics; Prediction; Single nucleotide polymorphism
Authors: S K Paulson; T A Kaprak; C J Gresk; D M Fast; M T Baratta; E G Burton; A P Breau; A Karim Journal: Biopharm Drug Dispos Date: 1999-09 Impact factor: 1.627
Authors: Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Ali Aboel Dahab; Dhia El-Hag; Gamal M Moutamed; Sarah Aboel Dahab; Ramadan Abuknesha; Norman W Smith Journal: Cancer Chemother Pharmacol Date: 2016-04-09 Impact factor: 3.333
Authors: Munir Pirmohamed; Girvan Burnside; Niclas Eriksson; Andrea L Jorgensen; Cheng Hock Toh; Toby Nicholson; Patrick Kesteven; Christina Christersson; Bengt Wahlström; Christina Stafberg; J Eunice Zhang; Julian B Leathart; Hugo Kohnke; Anke H Maitland-van der Zee; Paula R Williamson; Ann K Daly; Peter Avery; Farhad Kamali; Mia Wadelius Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245